Category: Federal Forum Posters
Purpose: Multiple daily injections (MDI) of basal-bolus insulin are often needed during the advanced stages of Type 2 Diabetes Mellitus in order to maintain glycemic control and prevent complications. Unfortunately, even with these more labor-intensive treatment regimens, 30% of patients are still unable to meet their glycated hemoglobin goal. Continuous subcutaneous insulin infusion (CSII) may serve as an alternative treatment method for these patients who remain uncontrolled with MDI. However, a negative perception surrounding the device complexity and safety has limited its use in the elderly population.
Methods: This retrospective chart review will examine the safety and efficacy of insulin pumps in a veteran population. Data will be extracted from the computerized patient record system (CPRS) and data warehouse for those patients with an active prescription for CSII from January 1st 2016 to January 1st 2018. Data analysis will include age, gender, ethnicity, duration of disease, glycated hemoglobin, insulin total daily dose, and incidence of hypoglycemia. The primary outcome is the reduction of glycated hemoglobin following at least 3 months of consistent CSII treatment. Secondary endpoints will include the reduction in total daily dose (TDD) of insulin, and the incidence of hypoglycemia.
Results: Not Applicable
Conclusion: Not Applicable
Laura Woodard– PGY1 Pharmacy Resident, Salem VA Medical Center, Roanoke, VA